Additionally, they observed the restauration of impaired erythroid differentiation in human RPS19-deficient CD34+ cord blood cells treated with this vector, underscoring its potential for clinical translation and therapeutic benefit in DBA patients [30]. This evidence concerns the gene RPS19 and Diamond-Blackfan anemia.